UVM Health Taps LunaPBC, Invitae on Genomic Testing Pilot Project
The pilot project will provide information for 147 genes that are well-established indicators of increased risk for certain diseases for which clinical treatment guidelines are established.
Many Doctors Not Discussing Genomic Test Costs with Patients
As the use of genomic testing increases, many doctors are failing to discuss the costs of these tests with their patients, leaving them at risk of unexpected medical bills.
![Biocept intends to become Thermo Fisher Scientific’s “Center of Excellence” for oncology-focused liquid biopsy efforts as part of a commercial collaboration by the companies. [© AlexRaths/iStock]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1555-218x150.jpeg "Lexent, Illumina Enter Partnership for Cancer Monitoring Liquid Biopsy Kits")
Lexent, Illumina Enter Partnership for Cancer Monitoring Liquid Biopsy Kits
Confera Dx is currently in development with the intention to be made available next year as a laboratory-developed test performed by Lexent in a CLIA-certified laboratory with the intention of developing a distributed in vitro diagnostic at a later date.
Vela Diagnostics Gets FDA Approval for HIV-1 NGS Assay
The Sentosa SQ HIV-1 Genotyping Assay uses the plasma of patients infected with human immunodeficiency virus-1 and is the first and only HIV-1 genotyping NGS assay currently available on the market to receive FDA marketing authorization.
Owlstone Medical, Thermo Fisher Forge Breath Biopsy Technology Collaboration
The collaboration will integrate Thermo Fisher’s Orbitrap gas chromatography mass spectrometry (GC-MS) instrumentation into Owlstone’s breath biopsy platform to conduct metabolomics studies for unique biomarkers.
PredictImmune Partners with Foundation on Study to Validate IBD Test
The test stratifies patients based on their risk of subsequently experiencing a severe disease course, which is characterized by the requirement for multiple escalations in treatment due to frequently relapsing or chronically active disease.
Treading with Caution: PGx Test Developers Pursue Dialogue as FDA Maintains Enforcement Stance
Developers of pharmacogenetic tests cheered in August when United Healthcare (UHC) concluded in a policy statement effective October 1, that “the use of pharmacogenetic...
2020 Vision: Industry Leaders Share Predictions of What May Shape Precision Medicine in the...
As 2020 approaches, it is fair to say that significant—and perhaps surprising—advances will be made in the precision medicine and omics arenas, as there...
Genetic Counseling 2.0
As genetic testing ramps up in the clinic and via consumer-oriented providers, companies leverage technology to scale genetic counseling services.
Promega to Develop MSI Technology as CDx to Merck’s Keytruda
Promega’s MSI testing is designed to functionally measure the genomic accumulation of insertion or deletion (INDEL) errors caused by a deficient mismatch-repair system (dMMR) that occurs in certain types of solid tumors.
